ATTAIN-OSA
2026
ATTAIN-OSA: A Master Protocol to Investigate Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight
In adults with moderate-to-severe obstructive sleep apnoea and obesity or overweight, with or without positive airway pressure, oral orforglipron reduced the apnoea-hypopnoea index at 52 weeks compared with placebo.
Result
Primary endpoint: Change in apnoea-hypopnoea index at 52 weeks
Trial 1: mean AHI change -17.8 with orforglipron vs -4.5 with placebo (difference -13.2; 95% CI -17.7 to -8.7; P < .001) at 52 weeks. Trial 2: -17.3 vs -5.3 (difference -12.0; 95% CI -17.1 to -6.9; P < .001). Of 7 key secondary end points, 6 were statistically significant. The change in PROMIS sleep-related impairment was not. Sleep apnoea-specific hypoxic burden difference -45.9 % min/h (95% CI -63.7 to -28.2) in trial 1 and -43.1 % min/h (95% CI -62.4 to -23.8) in trial 2. Body weight -10.4% vs -2.2% (difference -8.3%; 95% CI -9.8% to -6.7%) in trial 1 and -10.7% vs -1.1% (difference -9.6%; 95% CI -10.9% to -8.2%) in trial 2. Gastrointestinal events occurred in 68.0% vs 37.4% in trial 1 and 70.6% vs 36.6% in trial 2.
- Subtopic
- Weight-loss pharmacotherapy
- Design
- Phase 3 master protocol of two double-blind, placebo-controlled trials (Eli Lilly; 66 sites): once-daily oral orforglipron versus placebo for 52 weeks, one study in patients not using PAP, one in patients continuing PAP
- Enrolled
- 712 patients
- Source
- Malhotra A, Gottlieb DJ, et al. JAMA. 2026; published online 9 November.doi 10.1001/jama.2026.24080
Discussion & critique
Two double-blind, placebo-controlled trials show that orforglipron reduced the apnoea-hypopnoea index and hypoxic burden over 52 weeks, both in patients not using positive airway pressure and in those using it. The primary endpoint is a polysomnographic surrogate, and the trials report no cardiovascular or other clinical outcomes, while one key secondary patient-reported measure of sleep-related impairment did not reach significance. Gastrointestinal events occurred in roughly twice as many patients with orforglipron as with placebo, and follow-up is limited to one year. Most participants were men, with 31.4% and 26.9% women in the two trials.